by Blood
Scientists say myeloid-derived suppressor cells (MDSCs) engineered with human induced pluripotent stem cells (iPSC) may hold the key to migrating off-the-shelf MDSCs to the clinical setting, where...
by Nature
Tumor-specific antigens remain elusive in T-cell lymphomas (TCL), effectively limiting the impact of chimeric antigen receptor (CAR) T-cell therapy in this setting, but scientists are encouraged...
by Blood Advances
Researchers report favorably on the use of combined post-transplant cyclophosphamide (PTCy) and abatacept as prevention against graft-versus-host disease (GVHD) after allogeneic transplantation...
by Nature
Conventional conditioning methods ahead of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can lead to tissue damage and systemic toxicities in patients with Fanconi anemia (FA),...
by David Porter
On Wednesday, Sept. 10, ASTCT representatives with colleagues from NMDP went to Capitol Hill to advocate for NIH funding and greater access to care for the patients we serve.
by Shernan Holtan, MD
This spotlight features Shernan Holtan, MD, chief of blood and marrow transplantation at Roswell Park. A leader in regenerative therapies and GVHD research, she shares the early experiences that...